| $385M | ||
| $350M | ||
| $215M | ||
| $82M | ||
| $76M | ||
| $62M |
Buys | $26,071,310 | 20 | 71 |
Sells | $4,673,751 | 8 | 29 |
| EcoR1 Capital, LLC | 20 | $26.07M | 0 | $0 | $26.07M | |
| Hollywood Mark | EVP & Chief Operating Officer | 0 | $0 | 1 | $138,762 | $-138,762 |
| Smith Jeffrey T L | EVP & Chief Medical Officer | 0 | $0 | 2 | $475,561 | $-475,561 |
| Moore Paul Andrew | Chief Scientific Officer | 0 | $0 | 2 | $721,457 | $-721,457 |
| Galbraith Kenneth | Chair & CEO | 0 | $0 | 3 | $3.34M | $-3.34M |
Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, breast, and colorectal cancer; and ZW49, a biparatopic anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate that is in Phase 1 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. The company has strategic partnerships with Merck Sharp & Dohme Research Ltd.; Eli Lilly and Company; Bristol-Myers Squibb company; GlaxoSmithKline Intellectual Property Development Ltd.; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; BeiGene, Ltd.; and Exelixis, Inc. It also has licensing and research collaboration with LEO Pharma A/S to research, develop, and commercialize bispecific antibodies; and Iconic Therapeutics, Inc. Zymeworks Inc. was incorporated in 2003 and is headquartered in Vancouver, Canada.
Over the last 12 months, insiders at Zymeworks Inc. have bought $26.07M and sold $4.67M worth of Zymeworks Inc. stock.
On average, over the past 5 years, insiders at Zymeworks Inc. have bought $21.52M and sold $1.8M worth of stock each year.
Highest buying activity among insiders over the last 12 months: EcoR1 Capital, LLC () — $26.07M.
The last purchase of 5,919 shares for transaction amount of $69,738 was made by EcoR1 Capital, LLC () on 2025‑05‑19.
| 2026-01-12 | Sale | Galbraith Kenneth | Chair & CEO | 30,424 0.0396% | $22.67 | $689,819 | +0.09% | |
| 2026-01-12 | Sale | Hollywood Mark | EVP & Chief Operating Officer | 6,120 0.008% | $22.67 | $138,762 | +0.09% | |
| 2026-01-12 | Sale | Moore Paul Andrew | Chief Scientific Officer | 9,560 0.0124% | $22.67 | $216,759 | +0.09% | |
| 2026-01-12 | Sale | Smith Jeffrey T L | EVP & Chief Medical Officer | 9,310 0.0121% | $22.67 | $211,090 | +0.09% | |
| 2026-01-05 | Sale | Galbraith Kenneth | Chair & CEO | 54,343 0.0712% | $25.10 | $1.36M | -9.05% | |
| 2026-01-05 | Sale | Moore Paul Andrew | Chief Scientific Officer | 20,110 0.0263% | $25.10 | $504,699 | -9.05% | |
| 2026-01-05 | Sale | Smith Jeffrey T L | EVP & Chief Medical Officer | 10,538 0.0138% | $25.10 | $264,471 | -9.05% | |
| 2025-12-22 | Sale | Galbraith Kenneth | Chair & CEO | 47,528 0.0618% | $27.02 | $1.28M | -15.80% | |
| 2025-05-19 | EcoR1 Capital, LLC | 5,919 0.0085% | $11.78 | $69,738 | +45.14% | |||
| 2025-05-15 | EcoR1 Capital, LLC | 49,502 0.0704% | $11.43 | $565,847 | +47.53% | |||
| 2025-04-17 | EcoR1 Capital, LLC | 54,760 0.0869% | $11.52 | $630,819 | +43.02% | |||
| 2025-04-16 | EcoR1 Capital, LLC | 73,953 0.1138% | $11.16 | $825,589 | +46.44% | |||
| 2025-04-04 | EcoR1 Capital, LLC | 196,438 0.288% | $11.17 | $2.19M | +48.63% | |||
| 2025-04-03 | EcoR1 Capital, LLC | 120,770 0.1749% | $11.84 | $1.43M | +38.30% | |||
| 2025-04-02 | EcoR1 Capital, LLC | 74,360 0.1062% | $11.85 | $881,017 | +35.95% | |||
| 2025-04-01 | EcoR1 Capital, LLC | 48,658 0.0698% | $11.60 | $564,647 | +39.07% | |||
| 2025-03-31 | EcoR1 Capital, LLC | 4,397 0.0062% | $11.75 | $51,658 | +34.72% | |||
| 2025-03-26 | EcoR1 Capital, LLC | 43,848 0.0625% | $12.24 | $536,857 | +28.50% | |||
| 2025-03-25 | EcoR1 Capital, LLC | 53,501 0.0775% | $12.91 | $690,452 | +23.87% | |||
| 2025-03-24 | EcoR1 Capital, LLC | 22,689 0.0327% | $13.08 | $296,847 | +21.38% |
| EcoR1 Capital, LLC | 17883908 23.8973% | $451.21M | 45 | 0 | <0.0001% | |
| Galbraith Kenneth | Chair & CEO | 226842 0.3031% | $5.72M | 0 | 6 | |
| Hollywood Mark | EVP & Chief Operating Officer | 132913 0.1776% | $3.35M | 0 | 1 | |
| Moore Paul Andrew | Chief Scientific Officer | 48497 0.0648% | $1.22M | 0 | 5 | |
| Smith Jeffrey T L | EVP & Chief Medical Officer | 26708 0.0357% | $673,842.84 | 0 | 3 | |
| Redmile Group, LLC | 10 percent owner | 6075918 8.1189% | $153.3M | 1 | 0 | +63.8% |
| LILLY ELI & CO | 10 percent owner | 2898647 3.8733% | $73.13M | 0 | 17 | |
| Tehrani Ali | Chief Executive Officer | 260325 0.3479% | $6.57M | 1 | 6 | +12.44% |
| Polverino Anthony J. | Chief Scientific Officer | 30979 0.0414% | $781,600.17 | 0 | 1 | |
| Klompas Neil A | President & COO | 17032 0.0228% | $429,717.36 | 0 | 5 | |
| Josephson Neil | Chief Medical Officer | 14449 0.0193% | $364,548.27 | 1 | 1 | <0.0001% |
| Cox Troy | director | 7500 0.01% | $189,225.00 | 1 | 0 | <0.0001% |
| Astle Christopher | SVP & Chief Financial Officer | 6503 0.0087% | $164,070.69 | 0 | 3 | |
| HAUSMAN DIANA | Chief Medical Officer | 5377 0.0072% | $135,661.71 | 0 | 5 | |
| O'Driscoll Kathryn | Chief People Officer | 5003 0.0067% | $126,225.69 | 0 | 2 | |
| Priour James | Chief Commercial Officer | 2003 0.0027% | $50,535.69 | 0 | 1 | |
| Poon David Kai Yuen | See Remarks | 0 0% | $0 | 0 | 1 |
$21,345,882 | 83 | 94.45% | $1.8B | |
$47,419,530 | 58 | 17.20% | $1.69B | |
$1,376,668 | 53 | 18.46% | $1.77B | |
$678,065,999 | 37 | -13.32% | $1.66B | |
$1,603,489 | 30 | 98.90% | $1.96B | |
$62,927,079 | 29 | 14.02% | $2.05B | |
Zymeworks Inc. (ZYME) | $82,281,805 | 29 | -1.52% | $1.89B |
$8,195,601 | 23 | -12.08% | $2.07B | |
$18,854,717 | 21 | 22.51% | $1.98B | |
$135,656,796 | 20 | 30.66% | $1.68B | |
$154,554,190 | 14 | 29.60% | $1.65B | |
$144,557,026 | 13 | 0.49% | $1.91B | |
$2,859,892 | 10 | 29.21% | $1.88B | |
$94,976,497 | 10 | -10.72% | $1.97B | |
$93,268,646 | 8 | -37.22% | $1.88B | |
$4,623,072 | 7 | 11.07% | $2.11B | |
$666,380 | 5 | -16.60% | $2.13B | |
$7,605,533 | 5 | 17.10% | $1.91B | |
$3,200,000 | 5 | -11.36% | $1.76B |
| Increased Positions | 119 | +59.8% | 12M | +16.2% |
| Decreased Positions | 85 | -42.71% | 14M | -19.12% |
| New Positions | 47 | New | 6M | New |
| Sold Out Positions | 24 | Sold Out | 3M | Sold Out |
| Total Postitions | 233 | +17.09% | 72M | -2.92% |
| Ecor1 Capital, Llc | $611,472.00 | 30.63% | 22.97M | 0 | 0% | 2025-09-30 |
| Rubric Capital Management Lp | $125,395.00 | 6.28% | 4.71M | 0 | 0% | 2025-09-30 |
| Blackrock, Inc. | $106,201.00 | 5.32% | 3.99M | +195,261 | +5.15% | 2025-09-30 |
| Morgan Stanley | $106,070.00 | 5.31% | 3.98M | -193,029 | -4.62% | 2025-09-30 |
| Bvf Inc/Il | $104,847.00 | 5.25% | 3.94M | -370,294 | -8.59% | 2025-09-30 |
| Redmile Group, Llc | $98,647.00 | 4.94% | 3.71M | -444,877 | -10.72% | 2025-09-30 |
| Vanguard Group Inc | $57,351.00 | 2.87% | 2.15M | -310,259 | -12.59% | 2025-09-30 |
| Perceptive Advisors Llc | $55,653.00 | 2.79% | 2.09M | +815,389 | +63.94% | 2025-09-30 |
| Vestal Point Capital, Lp | $46,984.00 | 2.35% | 1.76M | +615,000 | +53.48% | 2025-09-30 |
| Ubs Am, A Distinct Business Unit Of Ubs Asset Management Ame | $45,533.00 | 2.28% | 1.71M | -749,050 | -30.45% | 2025-09-30 |